# BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers

> **NCT03888053** · PHASE1 · COMPLETED · sponsor: **Blue Blood Biotech Corp.** · enrollment: 14 (actual)

## Conditions studied

- Diabetic Foot Ulcer

## Interventions

- **BIOLOGICAL:** BB-101

## Key facts

- **NCT ID:** NCT03888053
- **Lead sponsor:** Blue Blood Biotech Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-28
- **Primary completion:** 2021-12-01
- **Final completion:** 2023-12-31
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888053, "BB-101 for Treatment of Diabetic Lower Leg and Foot Ulcers". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03888053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*